Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Janux Therapeutics
Deciphera Pharmaceuticals, LLC
Pfizer
Regeneron Pharmaceuticals
Seagen Inc.
Eli Lilly and Company
Genentech, Inc.
Flare Therapeutics Inc.
Vir Biotechnology, Inc.
Pliant Therapeutics, Inc.
Eli Lilly and Company
BioNTech SE
Janssen Research & Development, LLC
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Bayer
MOMA Therapeutics
Eli Lilly and Company
Genmab
Instil Bio
Aura Biosciences
Genentech, Inc.
C Ray Therapeutics
Shanghai Henlius Biotech
Kura Oncology, Inc.
Incyte Corporation
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
Janssen Research & Development, LLC
Eli Lilly and Company
Context Therapeutics Inc.
Nammi Therapeutics Inc
Janssen Research & Development, LLC
Janssen Research & Development, LLC
EMD Serono
EvolveImmune United, Inc
Janssen Research & Development, LLC
IDEAYA Biosciences
OncoC4, Inc.
Acerand Therapeutics Limited
Compass Therapeutics
AbbVie